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Abstract
Background—Provider-based research networks, such as the National Cancer Institute’s 
Community Clinical Oncology Program (CCOP), have been shown to facilitate the translation of 
evidence-based cancer care into clinical practice. As such, we compared utilization of laparoscopy 
and partial nephrectomy among patients with early-stage kidney cancer according to exposure to 
CCOP-affiliated providers.
Methods—Using linked SEER-Medicare data, we identified patients with T1aN0M0 kidney 
cancer treated with nephrectomy from 2000–2007. For each patient, we determined receipt of care 
from a CCOP physician or hospital and treatment with laparoscopy or partial nephrectomy. 
Adjusting for patient characteristics (e.g., age, gender, marital status) and other organizational 
features (e.g., community hospital, NCI-designated cancer center), we used multivariable logistic 
regression to estimate the association between each surgical innovation and CCOP affiliation.
Results—Over the study interval, we identified 1,578 (26.8%) patients treated by a provider with 
CCOP affiliation. Trends in laparoscopy and partial nephrectomy utilization remained similar 
between affiliated and non-affiliated providers (p≥0.05). Adjusting for patient characteristics, 
organizational features, and clustering, we noted no association between CCOP affiliation and the 
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use of laparoscopy (OR 1.11, 95% CI 0.81–1.53) or partial nephrectomy (OR 1.04, 95% CI 0.82–
1.32) despite the relatively higher receipt of these treatments in academic settings (p-values<0.05).
Conclusions—At a population-level, patients treated by providers affiliated with CCOP were no 
more likely to receive at least one of two surgical innovations for treatment of their kidney cancer, 
indicating perhaps a more limited scope to provider-based research networks as they pertain to 
translational efforts in cancer care.
Keywords
kidney neoplasm; translation research; diffusion of innovation; provider-based research networks; 
laparoscopy; nephrectomy
Introduction
While continued scientific advancement remains critical, the real-world dissemination and 
implementation of new medical knowledge plays an essential role in improving health for 
patients with cancer.1 Accordingly, key stakeholders, including the Institute of Medicine and 
the National Institutes of Health, have endorsed strategies designed to enhance the transfer 
of academic discovery into clinical practice.1–4 Provider-based research networks (PBRN), 
such as the National Cancer Institute’s Community Oncology Research Program (NCORP) 
and, its predecessor, the Community Clinical Oncology Program (CCOP)—act as one 
potential mechanism. These bidirectional collaborations between academic research centers 
and community physicians work to diversify clinical trial enrollment and have further 
facilitated the delivery of evidence-based care to patients with colon and breast 
malignancies, successfully traversing the “blue highways” of cancer research.3, 5–7
Although promising, data supporting CCOP as a conduit for dissemination and 
implementation have focused on interventions that also utilized these networks to complete 
trial enrollment.6–8 In genitourinary oncology, minimally invasive and nephron-sparing 
surgery mark two technological advances offering potential benefits to patients with early-
stage kidney cancer. When compared to open radical nephrectomy, laparoscopy affords 
more rapid convalescence while nephron-sparing (i.e., partial nephrectomy) better preserves 
renal function, thereby reducing long-term renal insufficiency.9–13 Unlike examples in colon 
and breast cancer, data supporting these interventions come largely from single institution or 
population-based observational studies rather than large-scale, multi-institutional clinical 
trials. As such, it remains unclear whether the avenues provided by CCOP would facilitate 
the adoption of these new treatments now featured in evidence-based guidelines for 
T1N0M0 kidney cancer.14
In this context, we used linked SEER-Medicare data to examine the relationship between 
CCOP—a network of 3,500 physicians and 390 hospitals in 34 states—and the utilization of 
laparoscopy and partial nephrectomy among patients with early-stage kidney cancer during a 
period of provider adoption.15, 16 By evaluating this potential translation mechanism, we can 
begin to optimize dissemination strategies for new technology in the care of patients with 
malignant conditions.
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We used linked data from the National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) Program and the Centers for Medicare & Medicaid Services to identify 
patients diagnosed with non-urothelial T1aN0M0 kidney from 2000 through 2007. SEER is 
a population-based cancer registry that collects data regarding incidence, treatment, and 
mortality representative of the US population.17 The Medicare program provides primary 
health insurance for 97% of the US population aged 65 or older.18 Successful linkage with 
CMS claims is achieved for over 90% of Medicare patients whose cancer-specific data are 
tracked by SEER.18
Study cohort and utilization of laparoscopic or partial nephrectomy
After identifying a preliminary cohort of 11,696 patients, we excluded patients enrolled in a 
Medicare managed care plan or without continuous enrollment in Medicare from 12 months 
prior to 6 months following surgery (or until death) to yield 7,911 patients. Next, we used a 
validated algorithm to determine the specific surgical procedure for each subject based on 
inpatient and physician claims using International Classification of Diseases, 9th revision, 
Clinical Modification and Current Procedural Terminology codes.19 After excluding patients 
with claims for ablative therapies, we identified a final analytic cohort of 5,894 patients 
treated with one of four procedures: open radical nephrectomy, open partial nephrectomy, 
laparoscopic radical nephrectomy, or laparoscopic partial nephrectomy. For the purpose of 
our analyses, we created two binary indicator variables for laparoscopic nephrectomy (i.e., 
radical and partial) and partial nephrectomy (i.e., open and laparoscopic), respectively.
Provider-based research network exposure variables
To explore the relationship with provider-based research networks, these data were then 
linked through the unique identifiers on the claims to physician and hospital CCOP network 
data from NCI’s CCOP program. As described previously,6, 7 we used the Unique Physician 
Identification Number (UPIN) or hospital identifier on Medicare claims to identify 
physicians and hospitals affiliated with CCOP. We defined CCOP exposure as treatment by 
any CCOP affiliated physician or hospital during the index procedure claim.
As secondary exposure variables, we further created binary variables for each of the 
following organizational factors: 1) NCI-designated cancer center; 2) NCI Cooperative 
Groups with kidney cancer portfolios (e.g., American College of Surgeons Oncology Group, 
Eastern Cooperative Oncology Group, Southwest Oncology Group); and 3) community 
hospital with limited or no affiliation with medical schools.
Patient-level covariates
For each patient, we used SEER data to determine age, gender, geography, race, marital 
status, year of cancer diagnosis and tumor grade. We also measured pre-existing 
comorbidity by using a modification of the Charlson index to identify co-morbid conditions 
from inpatient and physician claims submitted during the 12 months prior to the index 
admission for kidney cancer surgery.20 In addition, we utilized the Medicare/Medicaid 
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indicator of dual eligibility and a census-tract level estimate of high school education 
divided into equally-sized quartiles within each SEER region as measures of socioeconomic 
status.21, 22
Statistical Analysis
We first described the relationship between patient and organization characteristics and 
receipt of laparoscopy and partial nephrectomy using chi-squared testing. We then measured 
annual rates of laparoscopic and partial nephrectomy from 2000 through 2007 by dividing 
the number of patients treated with each approach, respectively, by the total number of 
patients treated surgically in each year and compared time trends according to CCOP 
affiliation.
Next, we fit separate multivariable logistic regression models to estimate the association 
between CCOP affiliation and each surgical approach (i.e., laparoscopy and partial 
nephrectomy). In each model, we controlled for patient characteristics (i.e., age, race, 
gender, marital status, socioeconomic position, comorbidity, tumor grade, year of diagnosis, 
and SEER region) and organizational factors (i.e., NCI-designated cancer center, NCI 
Cooperative Group membership, and community hospital status). Additionally, we used 
Generalized Estimation Equations (GEE) to account for the clustering of patients treated 
within the same hospitals.
Sensitivity Analyses
To assess the robustness of our findings, we performed additional sensitivity analyses. First, 
because our findings depend on our definition for CCOP affiliation, we developed a second 
continuous measure for the degree of CCOP exposure.6, 7 We defined a window of exposure 
time to represent the period in which patients may seek advice from physicians regarding 
choice of surgical procedure. As kidney cancer is diagnosed primarily by cross-sectional 
imaging, we defined the exposure time as the interval between abdominal computed 
tomography or magnetic resonance imaging and surgery. Because 60 percent of the study 
cohort had more than one imaging claim prior to surgery, we tested various exposure-time 
windows. Within each window, the proportion of claims from CCOP-affiliated physicians or 
hospitals out of all claims (CCOP and non-CCOP, cancer and non-cancer) was calculated to 
capture the degree of CCOP exposure. Second, since CCOP affiliation may be associated 
with other organizational features, especially NCI-designated cancer center and/or 
Cooperative Groups, we also refitted our models with the following organizational 
variables: 1) CCOP affiliation only; and 2) CCOP affiliation and community hospital.
All statistical testing was 2-sided, completed using SAS version 9.2 (SAS Institute, Cary, 
NC), and carried out at the 5% significance level. This study was deemed exempt by the 
Institutional Review Board at the University of North Carolina, Chapel Hill.
Results
From 2000 through 2007, we identified 2,090 (35.5%) and 1,759 (29.8%) patients with 
early-stage kidney cancer treated with laparoscopic nephrectomy and partial nephrectomy, 
respectively. As reported in Table 1, treatment with laparoscopic rather than open 
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nephrectomy was associated with older age, higher socioeconomic status, more recent 
treatment years, and lower comorbidity score (p<0.05, Table 1). Those treated with partial as 
opposed to radical nephrectomy were more likely to be less than 75 years old, male, 
married, and treated in the latter portion of the study period (p<0.05, Table 1).
CCOP-affiliated physicians or hospitals treated 1,578 (26.8%) patients over the study 
interval. Utilization of laparoscopy and partial nephrectomy did not differ by CCOP 
exposure (p=0.827 and p=0.656, respectively). These technologies were also more common 
at NCI centers, cooperative group-affiliated organizations, and non-community hospitals 
(Table 1). Figure 1 depicts annual rates of laparoscopic nephrectomy and partial 
nephrectomy stratified by CCOP affiliation, demonstrating similar trends between groups.
Adjusting for patient and organizational characteristics, we found no significant association 
between CCOP affiliation and either use of laparoscopic (OR 1.11, 95% CI 0.81–1.53) or 
partial nephrectomy (OR 1.04, 95% CI 0.82–1.32). In contrast, patients were more likely to 
received laparoscopic nephrectomy in cooperative group-affiliated hospitals (OR 1.59, 95% 
CI 1.19–2.11) or non-community hospitals (OR 1.35, 95% CI 1.06–1.69). Similarly, patients 
more frequently underwent nephron-sparing surgery at an NCI-designated cancer center 
(OR 2.88, 95% CI 2.07–4.01) or non-community hospital (OR 1.43, 95% CI 1.15–1.79). 
Our findings did not substantively change when considering the degree of CCOP affiliation 
nor when excluding potentially collinear organizational factors from our models.
Discussion
Laparoscopic and nephron-sparing surgery are widely accepted as two transformative 
surgical innovations in genitourinary oncology that offer enhanced recovery and reduced 
renal morbidity, respectively, for patients undergoing kidney surgery.9, 10, 12, 13 Multiple 
professional organizations (e.g., American Urological Association, European Association of 
Urology) now advocate for partial nephrectomy as the preferred treatment for patients with 
early-stage kidney cancer followed by laparoscopic surgery for those requiring radical 
nephrectomy.14, 23 Despite these recommendations, many patients presenting with renal 
malignancies continue to undergo cancer treatment without the benefit of these 
technological advances,24 highlighting the need for more effective delivery of what many 
consider to be higher-quality kidney cancer care.
Unlike the enhanced dissemination of evidence-based practices seen with colon and breast 
cancer,6, 7 exposure to CCOP was not associated with delivery of recommended care among 
a sample of Medicare beneficiaries with kidney cancer. Consistent with the existing 
literature, we found that patients treated in an academic research setting (i.e., NCI-
designated cancer center or Cooperative Group member) were more likely to receive 
laparoscopic and/or partial nephrectomy.15, 16, 25 However, these higher usage rates did not 
translate into greater utilization among patients cared for by physicians and hospitals 
affiliated with this cancer-specific PBRN. Taken together, these findings suggest that—
despite CCOP’s available infrastructure—persistent disconnect exists between academic 
centers and community practices, at least as it pertains to new surgical technologies in 
kidney cancer.
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Paradoxically, one challenge in advancing surgical innovations through CCOP may lie 
within the program’s deep roots in clinical trial development and implementation. Since its 
inception in 1983, CCOP has operated with a fundamental principle of engaging community 
providers in clinical trial design and subsequent translation into clinical practice.5 
Accounting for nearly one third of NCI-sponsored clinical trial participants, CCOP has been 
involved with a diverse array of experimental studies including large-scale trials in breast 
and colon cancer.38, 39 As such, CCOP has been well-positioned to propagate newly-
established, evidence-based practices in these cancer populations.5–7, 26, 27
However, owing to a variety of externalities, the evolution of new surgical technologies may 
proceed in a manner where randomized control trials become impractical, unethical, or 
inopportune.28–30 Accordingly, the IDEAL paradigm has been proposed for the evaluation 
and diffusion of surgical innovations. Herein, developmental studies, prospective registries, 
quasi-experimental designs, and long-term monitoring are embraced in addition to 
randomized control studies.31 Because the data supporting laparoscopic and partial 
nephrectomy have come primarily from single institution studies and population-level 
observational data,9–13 CCOP may not have been fully activated. In fact, survey data shortly 
following our study interval suggest that many community urologists, compared to their 
academic counterparts, considered partial nephrectomy to be preferable in only a subset of 
indicated cases, underscoring potential issues related to knowledge transfer.32, 33
Additionally, without the support and experience gained through trial participation, 
community providers may not be as well prepared to readily deliver new, effective cancer 
treatments. For laparoscopy and partial nephrectomy, physician training and experience 
serve as major determinants of technology adoption.15, 25, 34 For laparoscopic surgery, in 
particular, utilization appears to be strongly linked to a surgeon’s medical training, more so 
than his or her practice setting.15 In this context, lower use of laparoscopic and/or partial 
nephrectomy may be potentially appropriate if community urologist lack the requisite 
knowledge or technical expertise. Therefore, with clinical trials serving as the nexus for 
community–academic engagement, CCOP may not be as well suited to either disseminate or 
implement evidence-based surgical therapies that follow the IDEAL paradigm.
Our findings should be considered in the context of several limitations. First, as with any 
observational study, these data remain vulnerable to residual selection bias and/or 
unmeasured confounding. For example, discrepancies in tumor anatomy or surgical 
appropriateness may influence treatment selection and bias our findings. It can be argued, 
however, that such factors would affect treatment in an NCI-designated cancer center or 
Cooperative Group in a similar manner. Second, our measure for CCOP affiliation focuses 
on the physician and hospital performing the surgical procedure. Exposure to a CCOP-
affiliated provider or facility prior to but not during the surgical episode may potentially 
influence treatment utilization. However, we found no difference when extending the 
exposure window or when accounting for the degree of CCOP exposure. Third, the 
geographic footprints of SEER and NCI’s CCOP may not overlap precisely. That being said, 
CCOP sites exist in approximately three quarters of SEER registries nationwide, suggesting 
robust exposure at the population-level.
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These limitations notwithstanding, our findings have important implications for the delivery 
of quality cancer care. In response to the shifting landscape of US health care, the National 
Cancer Institute has bolstered its investment in PBRNs, replacing CCOP with the larger and 
more integrated Community Oncology Research Program (NCORP). Utilizing much of the 
preexisting infrastructure from CCOP, this newly established research platform aims to 
advance both clinical trial science and cancer care delivery research to improve health for 
patients with cancer. As part of this effort, NCORP will broaden its research agenda to 
include both longitudinal, observational data and post-treatment surveillance.35 Moving 
forward then, NCORP may become ideally positioned to rigorously assess surgical 
innovations according to the IDEAL paradigm. In turn, with more active engagement, 
NCORP may better facilitate the efficient dissemination of a broader array of new 
technologies.
Furthermore, with NCORP moving into cancer care delivery research, its extensive network 
may be well suited for large-scale, provider-based collaboratives focused on cancer care 
quality. Utilizing transparent, equitable, and bidirectional exchanges similar to CCOP and 
now NCORP, these entities actively disseminate, implement, and monitor care redesign. 
Examples in urology have enhanced the uptake of evidence-based guidelines for the 
radiographic evaluation of prostate cancer and intravesical therapy in bladder cancer. By 
coupling knowledge transfer with quality improvement, these efforts have overcome 
provider- and practice-level barriers to achieve high levels of recommendation 
adherence.36–38 With quality metrics already established through the American Society of 
Clinical Oncology’s Quality Oncology Practice Initiative, NCORP may extend the initial 
benefits generated by this voluntary program and further address residual quality gaps.39, 40 
So while CCOP was not associated with accelerated care delivery in the context of new 
kidney cancer surgeries, recent developments may expand the capacity of CCOP’s 
successor, NCORP, and other PBRNs to efficiently disseminate and effectively implement 
new surgical technologies in cancer care.
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Proportion of patients treated with laparoscopy (A) and the proportion of patients treated 
with partial nephrectomy (B) according to CCOP affiliation. Proportions are derived from 
the number of patients treated with either laparoscopy or partial nephrectomy divided by the 
number of patients treated surgically for each given year. Temporal trends compared using 
chi-squared testing.
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Table 2
Multivariable Models - Generalized Estimating Equation
Covariate
Laparoscopy Partial Nephrectomy
OR (95% CI) P-value OR (95% CI) P-value
Age at diagnosis
65–69 Ref Ref
70–74 0.98 (0.84–1.14) 0.749 0.90 (0.78–1.05) 0.179
75–79 1.08 (0.93–1.26) 0.324 0.74 (0.63–0.86) <0.001
80+ 1.24 (1.03–1.49) 0.023 0.44 (0.36–0.54) <0.001
Female 1.07 (0.95–1.20) 0.268 0.84 (0.73–0.97) 0.015
Race
Caucasian American Ref Ref
African American 0.89 (0.73–1.10) 0.285 0.94 (0.72–1.21) 0.607
Others 1.15 (0.86–1.54) 0.345 1.02 (0.73–1.42) 0.897
Married 0.94 (0.84–1.06) 0.326 1.02 (0.88–1.19) 0.790
Dual eligibility for Medicare/Medicaid 0.89 (0.74–1.07) 0.213 1.00 (0.80–1.24) 0.970
Non-high school graduate
Bottom Quartile Ref Ref
2nd Quartile 0.93 (0.79–1.09) 0.353 0.94 (0.81–1.10) 0.466
3rd Quartile 0.87 (0.75–1.02) 0.089 0.93 (0.77–1.13) 0.489
Top Quartile 0.87 (0.74–1.02) 0.088 0.88 (0.73–1.06) 0.167
Tumor Grade
Well differentiated 0.90 (0.73–1.13) 0.370 1.77 (1.40–2.24) <0.001
Moderately differentiated 0.86 (0.73–1.01) 0.061 1.30 (1.07–1.58) 0.009
Poorly differentiated / Undifferentiated Ref Ref
Unknown 0.82 (0.69–0.98) 0.030 1.56 (1.26–1.94) <0.001
Comorbidity Score ≥ 1 0.85 (0.76–0.96) 0.008 1.00 (0.88–1.14) 0.985
Year of diagnosis
2000 Ref Ref
2001 2.38 (1.51–3.76) <0.001 1.11 (0.83–1.47) 0.484
2002 4.28 (2.76–6.65) <0.001 1.25 (0.92–1.71) 0.156
2003 7.40 (4.84–11.31) <0.001 1.53 (1.15–2.03) 0.003
2004 9.88 (6.59–14.81) <0.001 1.87 (1.40–2.50) <0.001
2005 11.79 (7.94–17.51) <0.001 1.83 (1.38–2.42) <0.001
2006 14.74 (9.81–22.15) <0.001 2.22 (1.64–3.01) <0.001
2007 16.63 (11.14–24.82) <0.001 1.93 (1.44–2.60) <0.001
SEER Region
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Covariate
Laparoscopy Partial Nephrectomy
OR (95% CI) P-value OR (95% CI) P-value
San Francisco 1.70 (0.99–2.92) 0.055 1.29 (0.81–2.04) 0.284
Connecticut 1.37 (0.88–2.13) 0.162 0.81 (0.52–1.28) 0.370
Detroit 1.73 (1.04–2.87) 0.033 0.77 (0.51–1.15) 0.205
Hawaii 0.66 (0.29–1.47) 0.306 0.94 (0.49–1.78) 0.845
Iowa 0.76 (0.47–1.25) 0.283 0.73 (0.49–1.08) 0.117
New Mexico 0.81 (0.42–1.56) 0.523 0.97 (0.54–1.73) 0.919
Seattle 1.35 (0.81–2.26) 0.255 1.39 (0.88–2.20) 0.153
Utah 0.83 (0.45–1.54) 0.563 1.48 (0.88–2.48) 0.140
Atlanta and Rural Georgia 1.42 (0.62–3.26) 0.404 0.86 (0.46–1.62) 0.643
San Jose 0.92 (0.43–1.99) 0.837 0.15 (0.54–2.47) 0.717
Los Angeles 1.15 (0.77–1.72) 0.503 1.10 (0.75–1.60) 0.634
Greater California 1.26 (0.86–1.84) 0.242 0.94 (0.69–1.28) 0.691
Kentucky 1.02 (0.66–1.57) 0.922 1.03 (0.70–1.51) 0.897
Louisiana 1.24 (0.78–1.98) 0.369 1.03 (0.71–1.48) 0.883
New Jersey Ref Ref
CCOP affiliation 1.11 (0.81–1.53) 0.513 1.04 (0.82–1.32) 0.741
Cooperative Group 1.59 (1.19–2.11) 0.002 1.20 (0.96–1.50) 0.118
NCI-designated Cancer Center 1.49 (0.88–2.50) 0.136 2.88 (2.07–4.01) <0.001
Community Hospital 0.74 (0.59–0.94) 0.012 0.70 (0.56–0.87) 0.001
Abbreviations: SEER – Surveillance, Epidemiology, and End Results; CCOP – Community Clinical Oncology Program; NCI – National Cancer 
Institute.
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